5 Stocks With Crummy Sales Growth — NAVB CTEL HKTV CUR IMMU

by Portfolio Grader | September 16, 2013 2:30 pm

This week, these five stocks have the worst ratings in Sales Growth, one of the eight Fundamental Categories on Portfolio Grader[1].

Navidea Biopharmaceuticals, Inc. (AMEX:NAVB[2]) is focused on the development and commercialization of precision radiopharmaceutical diagnostics for diseases such as cancer. NAVB also gets F’s in Equity and Cash Flow. For more information, get Portfolio Grader’s complete analysis of NAVB stock[3].

City Telecom (H.K.) Ltd. (NASDAQ:CTEL[4]) provides fixed telecommunications networks and international telecommunications services for residential and corporate customers. CTEL gets F’s in Earnings Growth and Operating Margin Growth as well. For more information, get Portfolio Grader’s complete analysis of CTEL stock[5].

Hong Kong Television Network Ltd. Sponsored ADR (NASDAQ:HKTV[6]) engages in the provision of multimedia production and contents distribution business, and other multimedia related activities in Hong Kong. HKTV also gets F’s in Earnings Growth and Operating Margin Growth. For more information, get Portfolio Grader’s complete analysis of HKTV stock[7].

Neuralstem, Inc. (AMEX:CUR[8]) is a biotherapeutics company utilizing its Human Neural Stem Cell technology to develop cures for diseases of the CNS. CUR gets F’s in Analyst Earnings Revisions and Equity as well. For more information, get Portfolio Grader’s complete analysis of CUR stock[9].

Immunomedics, Inc. (NASDAQ:IMMU[10]) develops, manufactures, and sells diagnostic imaging and therapeutic products. IMMU also gets F’s in Earnings Growth, Equity, Cash Flow, and Operating Margin Growth. For more information, get Portfolio Grader’s complete analysis of IMMU stock[11].

Louis Navellier’s proprietary Portfolio Grader[1] stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here[12].

Endnotes:

  1. Portfolio Grader: https://navelliergrowth.investorplace.com/portfolio-grader/
  2. NAVB: https://navelliergrowth.investorplace.com/portfolio-grader/stock-report.html?t=NAVB
  3. For more information, get Portfolio Grader’s complete analysis of NAVB stock: https://navelliergrowth.investorplace.com/portfolio-grader/stock-report.html?t=NAVB
  4. CTEL: https://navelliergrowth.investorplace.com/portfolio-grader/stock-report.html?t=CTEL
  5. For more information, get Portfolio Grader’s complete analysis of CTEL stock: https://navelliergrowth.investorplace.com/portfolio-grader/stock-report.html?t=CTEL
  6. HKTV: https://navelliergrowth.investorplace.com/portfolio-grader/stock-report.html?t=HKTV
  7. For more information, get Portfolio Grader’s complete analysis of HKTV stock: https://navelliergrowth.investorplace.com/portfolio-grader/stock-report.html?t=HKTV
  8. CUR: https://navelliergrowth.investorplace.com/portfolio-grader/stock-report.html?t=CUR
  9. For more information, get Portfolio Grader’s complete analysis of CUR stock: https://navelliergrowth.investorplace.com/portfolio-grader/stock-report.html?t=CUR
  10. IMMU: https://navelliergrowth.investorplace.com/portfolio-grader/stock-report.html?t=IMMU
  11. For more information, get Portfolio Grader’s complete analysis of IMMU stock: https://navelliergrowth.investorplace.com/portfolio-grader/stock-report.html?t=IMMU
  12. here: https://navelliergrowth.investorplace.com/portfolio-grader/

Source URL: https://investorplace.com/2013/09/5-stocks-with-crummy-sales-growth-navb-ctel-hktv-cur-immu-navb-ctel-hktv-cur-immu/